Last mentioned: Mar 23, 2026
Product Transition
Hims & Hers expected to fully phase out compounded GLP-1s in favor of branded Ozempic.
Citi PT Reduction
Citi lowers its price target for GEHC, citing sector-wide headwinds.
Class Action Filed
Pomerantz Law Firm officially files a class action lawsuit against Gemini Space Station and its officers.
Workforce Cuts
Winklevoss brothers confirm a 30% reduction in staff; first shareholder lawsuit filed over strategy shift.
Market Crash
Citi downgrades GEMI; stock price collapses as reports of financial instability emerge.
Leadership Change
SEC filing details departure and election of directors and officers.
SNB Position
Swiss National Bank reports a $99.12 million stake in the company.
Strategic Settlement
Hims & Hers and Novo Nordisk announce a distribution partnership and lawsuit dismissal.
Market Surge
HIMS stock skyrockets 41% with record-breaking trading volume.
Analyst Consensus
Market analysts set a price target of $92.50 for GEHC stock.
Stock Surge
GEMI shares jump 30% as Bitcoin surpasses $73,000, buoyed by crypto-linked sentiment.
Material Agreement
Company enters into a material definitive agreement regarding financial obligations.
Quarterly Earnings
GE HealthCare reports results of operations and financial condition.
Legal Friction
Novo Nordisk files patent infringement lawsuits against telehealth providers selling compounded GLP-1s.
Citi has lowered its price target for GE HealthCare Technologies (GEHC) following a series of leadership changes and a broader reassessment of hospital capital expenditure trends. The move reflects a more cautious stance on the medical technology sector as providers navigate persistent inflationary pressures and budget constraints.
Citi has lowered its price target for GE HealthCare Technologies (GEHC), signaling a cautious outlook on the medical imaging giant's near-term growth trajectory. The adjustment reflects broader sector concerns regarding capital equipment spending and regional market volatility in the healthcare technology space.
Pomerantz Law Firm has initiated a class action against Gemini Space Station, Inc. (GEMI) and its leadership, alleging securities fraud. The legal action follows a turbulent week marked by a major stock crash, workforce reductions, and a controversial strategy shift.
Micron Technologies delivered a massive Q2 beat-and-raise, with revenue surging 196% year-over-year to $23.86 billion. Bank of America responded by hiking its price target to $500, citing a fundamental shift in the memory industry toward a durable, AI-led upcycle.
Micron Technologies delivered a massive Q2 beat-and-raise, prompting Bank of America to raise its price target to $500. Despite a 196% revenue surge driven by AI memory demand, shares dipped 5% as markets digested the blockbuster print.
Netflix shares climbed following a bullish upgrade from Citi, which highlighted the streaming giant's ability to leverage price hikes and aggressive share buybacks. The move signals a shift in investor focus toward the company's robust free cash flow and maturing business model.
Netflix shares climbed following a bullish upgrade from Citi, which cited the streaming giant's ability to implement price hikes and its aggressive share buyback strategy. The move underscores Netflix's transition from a growth-focused disruptor to a highly profitable market leader with robust cash flow.
Citi has downgraded its growth projections for Bitcoin and Ether, citing a lack of progress on comprehensive US digital asset legislation. The bank's shift reflects growing institutional frustration with the legislative stalemate in Washington, which continues to hinder bank-led crypto services.
Citi has downgraded its market outlook for Bitcoin and Ether, citing the continued lack of legislative progress in the United States. The bank's shift highlights growing institutional frustration with the current 'regulation by enforcement' model and the stalled progress of key digital asset bills.
Citigroup has downgraded its investment rating for the Gemini cryptocurrency exchange following a significant reduction in price targets for Bitcoin and Ethereum. The move signals a more cautious stance from traditional financial institutions regarding the growth trajectory of digital asset infrastructure in 2026.
Indian benchmark indices, Sensex and Nifty 50, are attempting a fragile recovery following a technical correction triggered by Middle East tensions. While domestic institutional buying provides a floor, persistent foreign outflows and Brent crude prices exceeding $100 per barrel remain significant headwinds.
Hims & Hers Health shares skyrocketed following a strategic partnership with Novo Nordisk to distribute branded GLP-1 medications, effectively ending a high-stakes patent dispute. The agreement shifts the telehealth provider's weight-loss strategy from controversial compounded versions to FDA-approved Ozempic, significantly de-risking its long-term growth profile.
Hims & Hers Health shares skyrocketed 41% following a strategic agreement with Novo Nordisk to distribute branded GLP-1 medications, including Ozempic, directly through its telehealth platform. The deal effectively ends a high-stakes patent dispute and transitions the company away from controversial compounded formulations toward FDA-approved branded therapies.
Hims & Hers Health has secured a strategic partnership with Novo Nordisk to distribute branded GLP-1 medications, effectively ending a high-stakes patent dispute. The deal marks a pivotal shift for the telehealth provider from compounded alternatives to FDA-approved Ozempic, triggering a massive 41% rally in its share price.